特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
229744

脳卒中:パイプライン製品の分析

Stroke - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 716 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
脳卒中:パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 716 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

脳卒中とは、酸素不足のために脳細胞が突然死するという症状です。症状は突然かつ急速に生じ、短時間(通常は数分~数時間)で終了します。最初のうちは、患者は体調が悪く感じ、顔面が蒼白となり、気分も非常に悪くなります。また、突然の頭痛に悩まされることもあります。突然に顔面や手足、特に身体の片側が痺れる場合もあります。ろれつが回らない、話された内容を理解できない、視力が低下する、歩いたりバランスを取るのが難しくなる、という症状が出ることもあります。

当レポートでは、世界各国での脳卒中治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

脳卒中の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Stroke, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..11), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..12), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Stroke - Pipeline by AbbVie Inc, H1 2020
  • Stroke - Pipeline by Acorda Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Acticor Biotech SAS, H1 2020
  • Stroke - Pipeline by advanceCor GmbH, H1 2020
  • Stroke - Pipeline by Advanced BioMatrix Inc, H1 2020
  • Stroke - Pipeline by AegisCN LLC, H1 2020
  • Stroke - Pipeline by Aegle Therapeutics Corp, H1 2020
  • Stroke - Pipeline by Affibody AB, H1 2020
  • Stroke - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020
  • Stroke - Pipeline by Allosteros Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Anavex Life Sciences Corp, H1 2020
  • Stroke - Pipeline by Ankasa Regenerative Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Annovis Bio Inc, H1 2020
  • Stroke - Pipeline by Anthos Therapeutics Inc, H1 2020
  • Stroke - Pipeline by AntiRadical Therapeutics LLC, H1 2020
  • Stroke - Pipeline by Antoxis Ltd, H1 2020
  • Stroke - Pipeline by Apellis Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Aposcience AG, H1 2020
  • Stroke - Pipeline by APT Therapeutics Inc, H1 2020
  • Stroke - Pipeline by AptaTargets SL, H1 2020
  • Stroke - Pipeline by AriBio, H1 2020
  • Stroke - Pipeline by ArmaGen Inc, H1 2020
  • Stroke - Pipeline by Aronora Inc, H1 2020
  • Stroke - Pipeline by Artelo Biosciences Inc, H1 2020
  • Stroke - Pipeline by ArunA Biomedical Inc, H1 2020
  • Stroke - Pipeline by Asta Pharmaceuticals Co Ltd, H1 2020
  • Stroke - Pipeline by AstraZeneca Plc, H1 2020
  • Stroke - Pipeline by Athersys Inc, H1 2020
  • Stroke - Pipeline by Aurum Biosciences Ltd, H1 2020
  • Stroke - Pipeline by Australia Medical Industries Pty Ltd, H1 2020
  • Stroke - Pipeline by Avilex Pharma ApS, H1 2020
  • Stroke - Pipeline by Axolo Pharma Inc, H1 2020
  • Stroke - Pipeline by Band Therapeutics LLC, H1 2020
  • Stroke - Pipeline by Bayer AG, H1 2020
  • Stroke - Pipeline by Baylx Inc, H1 2020
  • Stroke - Pipeline by Beijing Yinfeng Dingcheng Bioengineering Co Ltd, H1 2020
  • Stroke - Pipeline by Bilix Co Ltd, H1 2020
  • Stroke - Pipeline by BioAxone BioSciences Inc, H1 2020
  • Stroke - Pipeline by Biogen Inc, H1 2020
  • Stroke - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Stroke - Pipeline by Brain-Gen LLC, H1 2020
  • Stroke - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Stroke - Pipeline by CardioVascular BioTherapeutics Inc, H1 2020
  • Stroke - Pipeline by Celltrion Inc, H1 2020
  • Stroke - Pipeline by Cenyx Biotech Inc, H1 2020
  • Stroke - Pipeline by Cerebrum Therapeutics Inc, H1 2020
  • Stroke - Pipeline by CHA Biotech Co Ltd, H1 2020
  • Stroke - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Cogentis Therapeutics Inc, H1 2020
  • Stroke - Pipeline by CohBar Inc, H1 2020
  • Stroke - Pipeline by Constant Therapeutics LLC, H1 2020
  • Stroke - Pipeline by Creative Medical Technology Holdings Inc, H1 2020
  • Stroke - Pipeline by Crioestaminal Saude e Tecnologia SA, H1 2020
  • Stroke - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
  • Stroke - Pipeline by Curacle Co Ltd, H1 2020
  • Stroke - Pipeline by CuroNZ Ltd, H1 2020
  • Stroke - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Stroke - Pipeline by DeckTherapeutics Inc, H1 2020
  • Stroke - Pipeline by Deha Pharmaceutical LLC, H1 2020
  • Stroke - Pipeline by DiaMedica Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Edvince AB, H1 2020
  • Stroke - Pipeline by EIP Pharma LLC, H1 2020
  • Stroke - Pipeline by Emerald Organic Products Inc, H1 2020
  • Stroke - Pipeline by Epigen Biosciences Inc, H1 2020
  • Stroke - Pipeline by Epygen Biotech Pvt Ltd, H1 2020
  • Stroke - Pipeline by Ever Supreme Bio Technology Co Ltd, H1 2020
  • Stroke - Pipeline by Evgen Pharma Plc, H1 2020
  • Stroke - Pipeline by eXithera Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Exscien Corp, H1 2020
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Stroke - Pipeline by Fortuna Fix Inc, H1 2020
  • Stroke - Pipeline by Freeox Biotech SL, H1 2020
  • Stroke - Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020
  • Stroke - Pipeline by GABA Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Genentech Inc, H1 2020
  • Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H1 2020
  • Stroke - Pipeline by Glucox Biotech AB, H1 2020
  • Stroke - Pipeline by GNT Pharma Co Ltd, H1 2020
  • Stroke - Pipeline by Guangzhou Cellprotek Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Guangzhou Recomgen Biotech Co Ltd, H1 2020
  • Stroke - Pipeline by Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Gwoxi Stem Cell Applied Technology Co Ltd, H1 2020
  • Stroke - Pipeline by Hefei Industrial Pharmaceutical Institute Co Ltd, H1 2020
  • Stroke - Pipeline by Hefei Medical & Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Hemostemix Inc, H1 2020
  • Stroke - Pipeline by Hibernaid Inc, H1 2020
  • Stroke - Pipeline by Hillhurst Biopharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Hope Biosciences LLC, H1 2020
  • Stroke - Pipeline by HSRx Group, H1 2020
  • Stroke - Pipeline by Immunwork Inc, H1 2020
  • Stroke - Pipeline by Instituto Biomar SA, H1 2020
  • Stroke - Pipeline by International Stem Cell Corp, H1 2020
  • Stroke - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020
  • Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Jiangsu Ouwei Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by JT Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Kai Nuo Bio Sci Co Ltd, H1 2020
  • Stroke - Pipeline by Kyoto Drug Discovery & Development Co Ltd, H1 2020
  • Stroke - Pipeline by Les Laboratoires Servier SAS, H1 2020
  • Stroke - Pipeline by Living Cell Technologies Ltd, H1 2020
  • Stroke - Pipeline by Lixte Biotechnology Holdings Inc, H1 2020
  • Stroke - Pipeline by LTT Bio-Pharma Co Ltd, H1 2020
  • Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H1 2020
  • Stroke - Pipeline by M et P Pharma AG, H1 2020
  • Stroke - Pipeline by Mapreg SAS, H1 2020
  • Stroke - Pipeline by Marizyme Inc, H1 2020
  • Stroke - Pipeline by Meridigen Biotech Co Ltd, H1 2020
  • Stroke - Pipeline by MetiMedi Pharmaceuticals Co Ltd, H1 2020
  • Stroke - Pipeline by Mitoconix Bio Ltd, H1 2020
  • Stroke - Pipeline by Modulation Therapeutics Inc, H1 2020
  • Stroke - Pipeline by NC Medical Research Inc, H1 2020
  • Stroke - Pipeline by NeuExcell Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Neuraly Inc, H1 2020
  • Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H1 2020
  • Stroke - Pipeline by NeurExo Sciences LLC, H1 2020
  • Stroke - Pipeline by Neurodon LLC, H1 2020
  • Stroke - Pipeline by NeuroFix Therapeutics LLC, H1 2020
  • Stroke - Pipeline by NeuroNascent Inc, H1 2020
  • Stroke - Pipeline by NeurOp Inc, H1 2020
  • Stroke - Pipeline by NeuroTrauma Sciences LLC, H1 2020
  • Stroke - Pipeline by Neurotrope Bioscience Inc, H1 2020
  • Stroke - Pipeline by New World Laboratories Inc, H1 2020
  • Stroke - Pipeline by Nipro Corp, H1 2020
  • Stroke - Pipeline by NoNO Inc, H1 2020
  • Stroke - Pipeline by Novago Therapeutics AG, H1 2020
  • Stroke - Pipeline by Novartis AG, H1 2020
  • Stroke - Pipeline by NuvOx Pharma LLC, H1 2020
  • Stroke - Pipeline by Nyrada Inc, H1 2020
  • Stroke - Pipeline by Omniox Inc, H1 2020
  • Stroke - Pipeline by OTR3 SAS, H1 2020
  • Stroke - Pipeline by Paracelsus Neuroscience I LLC, H1 2020
  • Stroke - Pipeline by Park Active Molecules, H1 2020
  • Stroke - Pipeline by Pharmagenesis Inc, H1 2020
  • Stroke - Pipeline by PharmatrophiX Inc, H1 2020
  • Stroke - Pipeline by Pharmazz Inc, H1 2020
  • Stroke - Pipeline by Pharmicell Co Ltd, H1 2020
  • Stroke - Pipeline by Phoenix Biotechnology Inc, H1 2020
  • Stroke - Pipeline by PhytoHealth Corp, H1 2020
  • Stroke - Pipeline by Prediction BioSciences SAS, H1 2020
  • Stroke - Pipeline by Primary Peptides Inc, H1 2020
  • Stroke - Pipeline by Protheragen Inc, H1 2020
  • Stroke - Pipeline by Q Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Regenera Pharma Ltd, H1 2020
  • Stroke - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by ReNetX Bio, H1 2020
  • Stroke - Pipeline by ReNeuron Group Plc, H1 2020
  • Stroke - Pipeline by Rich Pharmaceuticals Inc, H1 2020
  • Stroke - Pipeline by Rubicon Biotechnology Inc, H1 2020
  • Stroke - Pipeline by Saje Pharma LLC, H1 2020
  • Stroke - Pipeline by SanBio Inc, H1 2020
  • Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H1 2020
  • Stroke - Pipeline by Saniona AB, H1 2020
  • Stroke - Pipeline by Sansho Co Ltd, H1 2020
  • Stroke - Pipeline by Savara Inc, H1 2020
  • Stroke - Pipeline by Seneca Biopharma Inc, H1 2020
  • Stroke - Pipeline by Sentan Pharma Inc, H1 2020
  • Stroke - Pipeline by Shanghai Angecon Biotechnology Corp, H1 2020
  • Stroke - Pipeline by Shanghai SIMR Biotech Co Ltd, H1 2020
  • Stroke - Pipeline by Shanghai Zhimeng Biopharma Inc, H1 2020
  • Stroke - Pipeline by Shin Poong Pharm Co Ltd, H1 2020
  • Stroke - Pipeline by Shionogi & Co Ltd, H1 2020
  • Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2020
  • Stroke - Pipeline by Stemedica Cell Technologies Inc, H1 2020
  • Stroke - Pipeline by Stemetix Inc, H1 2020
  • Stroke - Pipeline by Stream Biomedical Inc, H1 2020
  • Stroke - Pipeline by SunBio Inc, H1 2020
  • Stroke - Pipeline by Suzhou Pharmavan Cancer Research Center Co Ltd, H1 2020
  • Stroke - Pipeline by Suzhou Ribo Life Sciences Co Ltd, H1 2020
  • Stroke - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
  • Stroke - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2020
  • Stroke - Pipeline by Techfields Pharma Co Ltd, H1 2020
  • Stroke - Pipeline by The Cell Factory BVBA, H1 2020
  • Stroke - Pipeline by TheraSource LLC, H1 2020
  • Stroke - Pipeline by Theratome Bio Inc, H1 2020
  • Stroke - Pipeline by Thrombolytic Science International LLC, H1 2020
  • Stroke - Pipeline by TikoMed AB, H1 2020
  • Stroke - Pipeline by TMS Co Ltd, H1 2020
  • Stroke - Pipeline by Translational Sciences Inc, H1 2020
  • Stroke - Pipeline by Valin Technologies Ltd, H1 2020
  • Stroke - Pipeline by Vanworld Pharmaceutical (Rugao) Company Ltd, H1 2020
  • Stroke - Pipeline by Vect-Horus SAS, H1 2020
  • Stroke - Pipeline by Verseon Corp, H1 2020
  • Stroke - Pipeline by Virogenomics BioDevelopment Inc, H1 2020
  • Stroke - Pipeline by Virtici LLC, H1 2020
  • Stroke - Pipeline by Xcelthera INC, H1 2020
  • Stroke - Pipeline by Xonovo Inc, H1 2020
  • Stroke - Pipeline by Yantai YenePharma Co Ltd, H1 2020
  • Stroke - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2020
  • Stroke - Pipeline by Zhejiang Ausun Pharmaceutical Co Ltd, H1 2020
  • Stroke - Pipeline by Zocere Inc, H1 2020
  • Stroke - Pipeline by ZyVersa Therapeutics Inc, H1 2020
  • Stroke - Pipeline by ZZ Biotech LLC, H1 2020
  • Stroke - Dormant Projects, H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..9), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..10), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..11), H1 2020
  • Stroke - Dormant Projects, H1 2020 (Contd..12), H1 2020
  • Stroke - Discontinued Products, H1 2020
  • Stroke - Discontinued Products, H1 2020 (Contd..1), H1 2020
  • Stroke - Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

  • Number of Products under Development for Stroke, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12181IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H1 2020, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 38, 23, 1, 2, 132, 17 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 33 and 5 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Stroke - Overview
  • Stroke - Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Drug Profiles
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.